Archives

Growth supported by the high-throughput genomic sequencing laboratory in Evry Continued sequencing activities on platforms operated on behalf of third parties supported by new clinical research projects in oncology

EVRY, FRANCE, FRIDAY JANUARY 13TH 2023, 7.30AM CET – IntegraGen (FR0010908723 – ALINT), an OncoDNA Group company specializing in the decryption of (…)  » 

Better profitability despite the inflation Confirmed growth outlook for the 2022 financial year Increase in services provided to platforms operated on behalf of third parties

EVRY, FRANCE, TUESDAY OCTOBER 18TH 2022, 7.30AM – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption (…)  » 

Continued sustained growth associated with the company’s sequencing platform in Évry and long-term contracts Strong revenue growth linked with microbiology sequencing

Evry, France, Wednesday July 13th 2022, 7.30am – IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs (…)  » 

Positive EBITDA and net result  Large increase in services delivered for the SeqOIA GCS and the P2M platform operated for Institut Pasteur  Limited negative impact from the pandemic along the year Outlook: continued revenues growth for 2022 based on orders book

Évry, France, april 29TH 2022 – 6.00pm (…)  » 

Significant increase in services delivered by SeqOIA and the Mutualized Microbiology (P2M) platform operated on behalf of the Institut Pasteur Stability of sequencing services provided by the Evry laboratory

EVRY, FRANCE, FRIDAY 14 JANUARY 2021, 7.30 – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA group (…)  » 

Slight revenue growth despite the impact of the pandemic during the first half of the year. Strong increase in order intake sets the stage for an anticipated dynamic growth during the second half of the 2021.

EVRY, FRANCE, FRIDAY 16 JULY 2021, 7.30AM – IntegraGen (FR0010908723 – ALINT (…)  »